561-P: Advancing Clinical Proficiency in Insulin Management through Case-Based Education

Objectives: Advances in mealtime insulin therapy and delivery technology can improve postprandial glucose, yet many healthcare professionals (HCPs) have significant knowledge and skills deficits regarding the fundamentals of prandial insulin therapy. This accredited educational activity sought to improve HCPs' ability to use newer types of prandial insulin, engage in patient-centered discussions, and adjust insulin doses. Methods: The online activity emphasized case-based teaching using standardized patient-provider videos to simulate telehealth visits. HCPs applied the latest evidence (via case scenarios) to real-life management of patients with insulin-treated diabetes. Interpretation of ambulatory blood glucose records and insulin dosing was emphasized. Point-of-care practice aids were provided to reinforce and enhance translation into clinical practice. Results: Participation: 3,013 US-based HCPs - 30% endocrinologists, 40% PCPs, 27% NPs/PAs, 3% other HCPs Assessment - Pre- (N=602) and post- (N=460) Skills Enhancement:ul54% absolute gain in ability to incorporate newer options and advances in mealtime insulin (25% to 78%)/ulul50% absolute gain in ability to engage in patient-centered discussions (29% to 79%)/ulImpact on Practice:ul28% absolute gain in intention to frequently or always assess time in range (TIR) as a measure of glycemic control (63% to 91%)/ulul41% absolute gain in intention to frequently or always use continuous glucose monitoring to assess blood glucose patterns (47% to 88%)/ulul18% absolute gain in willingness to ask patients frequently or always about their preferences for monitoring and insulin delivery devices (78% to 96%)/ulConclusion: Simulated telehealth visits with case-based teaching improved HCPs’ insulin administration skills and patient-centered practices. The substantial participation from diverse HCP backgrounds and the demonstrated improvements in key competencies underscore the initiative's relevance and effectiveness. Disclosure M.J. Tamas: None. M. Beyer: None. L.M. Novak: Speaker's Bureau; Abbott. Consultant; Abbott. Advisory Panel; Ascensia Diabetes Care, Boehringer-Ingelheim. Speaker's Bureau; BI Lilly Aliance. Advisory Panel; Medtronic, Novo Nordisk. Consultant; Novo Nordisk. Speaker's Bureau; Novo Nordisk, Sanofi, Xeris Pharmaceuticals, Inc. S. O'Brien: None. H.N. Drew: None. Funding Lilly (A-30576)